LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Начало・Списък с акции・Cogent Biosciences Inc

Cogent Biosciences Inc

Затворен

35.68 5.31

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

Максимум

37.06

Ключови измерители
By Trading Economics
Приходи	-22M -102M
EPS	-0.5
Служители	258
EBITDA	-30M -109M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+54.56% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	399M 6B
Предишно отваряне	30.37
Предишно затваряне	35.68

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

4.88 / 5.87 Подкрепа & съпротива

Cogent Biosciences Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.03.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Central Bank Decisions -2-

15.03.2026 г., 21:14 ч. UTC

Значими събития в новините

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

16.03.2026 г., 00:00 ч. UTC

Значими събития в новините

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

15.03.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

15.03.2026 г., 23:44 ч. UTC

Пазарно говорене

Значими събития в новините

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

15.03.2026 г., 23:35 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

15.03.2026 г., 23:00 ч. UTC

Придобивния, сливания и поглъщания

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

15.03.2026 г., 22:37 ч. UTC

Пазарно говорене

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

15.03.2026 г., 22:18 ч. UTC

Пазарно говорене

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

15.03.2026 г., 22:14 ч. UTC

Печалби

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

15.03.2026 г., 22:00 ч. UTC

Значими събития в новините

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15.03.2026 г., 22:00 ч. UTC

Значими събития в новините

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

15.03.2026 г., 03:00 ч. UTC

Значими събития в новините

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

14.03.2026 г., 15:00 ч. UTC

Значими събития в новините

Iran War Delivers Windfall to America's Oil Country -- WSJ

14.03.2026 г., 02:03 ч. UTC

Печалби

This Copper Stock Is Worth Mining for Profits -- Barrons.com

14.03.2026 г., 01:32 ч. UTC

Придобивния, сливания и поглъщания

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

14.03.2026 г., 00:29 ч. UTC

Придобивния, сливания и поглъщания

13D Filings -- Barrons.com

13.03.2026 г., 22:27 ч. UTC

Пазарно говорене

Значими събития в новините

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

13.03.2026 г., 22:13 ч. UTC

Пазарно говорене

Значими събития в новините

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

13.03.2026 г., 22:04 ч. UTC

Пазарно говорене

Значими събития в новините

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

13.03.2026 г., 22:00 ч. UTC

Придобивния, сливания и поглъщания

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

13.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

13.03.2026 г., 20:50 ч. UTC

Пазарно говорене

Значими събития в новините

Financial Services Roundup: Market Talk

13.03.2026 г., 20:02 ч. UTC

Пазарно говорене

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

13.03.2026 г., 19:50 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

13.03.2026 г., 19:35 ч. UTC

Значими събития в новините

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Cogent Biosciences Inc Прогноза

Ценова цел

By TipRanks

54.56% нагоре

12-месечна прогноза

Среден 52.55 USD 54.56%

Висок 64 USD

Нисък 35 USD

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Cogent Biosciences Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

12 ratings

Купи

Задържане

Продай

Според 12 анализатори, дали борсови рейтинги на Cogent Biosciences Inc през последните 3 месеца.

Техническа оценка

By Trading Central

4.88 / 5.87Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.